Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 200

1.

The clinical presentation and prognostic factors for intrahepatic and extrahepatic cholangiocarcinoma in a tertiary care centre.

Singal AG, Rakoski MO, Salgia R, Pelletier S, Welling TH, Fontana RJ, Lok AS, Marrero JA.

Aliment Pharmacol Ther. 2010 Mar;31(6):625-33. doi: 10.1111/j.1365-2036.2009.04218.x. Epub 2009 Dec 10.

2.

Factors influencing postoperative morbidity, mortality, and survival after resection for hilar cholangiocarcinoma.

Su CH, Tsay SH, Wu CC, Shyr YM, King KL, Lee CH, Lui WY, Liu TJ, P'eng FK.

Ann Surg. 1996 Apr;223(4):384-94.

3.

Prognostic factors of intrahepatic cholangiocarcinoma after hepatic resection: univariate and multivariate analysis.

Hanazaki K, Kajikawa S, Shimozawa N, Shimada K, Hiraguri M, Koide N, Adachi W, Amano J.

Hepatogastroenterology. 2002 Mar-Apr;49(44):311-6.

PMID:
11995440
4.

Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.

Chantajitr S, Wilasrusmee C, Lertsitichai P, Phromsopha N.

J Hepatobiliary Pancreat Surg. 2006;13(6):537-42. Epub 2006 Nov 30.

PMID:
17139428
5.

CD10+ fibroblasts are more involved in the progression of hilar/extrahepatic cholangiocarcinoma than of peripheral intrahepatic cholangiocarcinoma.

Nishihara Y, Aishima S, Hayashi A, Iguchi T, Fujita N, Taketomi A, Honda H, Tsuneyoshi M.

Histopathology. 2009 Oct;55(4):423-31. doi: 10.1111/j.1365-2559.2009.03398.x.

PMID:
19817893
6.

Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma.

Li SQ, Liang LJ, Hua YP, Peng BG, He Q, Lu MD, Chen D.

Chin Med J (Engl). 2009 Oct 5;122(19):2286-91.

PMID:
20079127
7.

Prognostic significance of lymph node metastasis and surgical margin status for distal cholangiocarcinoma.

Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Ohge H, Sueda T.

J Surg Oncol. 2007 Mar 1;95(3):207-12.

PMID:
17278119
8.
9.

Resection of hilar cholangiocarcinoma.

Strasberg SM.

HPB Surg. 1998;10(6):415-8.

10.

Resection of hilar cholangiocarcinoma: concomitant liver resection decreases hepatic recurrence.

Ito F, Agni R, Rettammel RJ, Been MJ, Cho CS, Mahvi DM, Rikkers LF, Weber SM.

Ann Surg. 2008 Aug;248(2):273-9. doi: 10.1097/SLA.0b013e31817f2bfd.

PMID:
18650638
11.

Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection.

Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, D'Angelica M, DeMatteo RP, Fong Y, Schwartz L, Kemeny N, O'Reilly E, Abou-Alfa GK, Shimada H, Blumgart LH, Jarnagin WR.

Ann Surg. 2008 Jul;248(1):84-96. doi: 10.1097/SLA.0b013e318176c4d3.

PMID:
18580211
12.

[An analysis on prognostic factors of hilar cholangiocarcinoma].

Zhou LX, Zhang ZW, Xu ZY.

Zhonghua Yi Xue Za Zhi. 2009 May 12;89(18):1275-7. Chinese.

PMID:
19595185
13.

The concept of perihilar cholangiocarcinoma is valid.

Ebata T, Kamiya J, Nishio H, Nagasaka T, Nimura Y, Nagino M.

Br J Surg. 2009 Aug;96(8):926-34. doi: 10.1002/bjs.6655.

PMID:
19591162
14.

Expression of matrix metalloproteinase 7 is an unfavorable postoperative prognostic factor in cholangiocarcinoma of the perihilar, hilar, and extrahepatic bile ducts.

Itatsu K, Zen Y, Yamaguchi J, Ohira S, Ishikawa A, Ikeda H, Sato Y, Harada K, Sasaki M, Sasaki M, Sakamoto H, Nagino M, Nimura Y, Ohta T, Nakanuma Y.

Hum Pathol. 2008 May;39(5):710-9. doi: 10.1016/j.humpath.2007.09.016. Epub 2008 Mar 10.

PMID:
18329694
15.

[Prognostic factors and long term outcome after surgery for hilar cholangiocarcinoma. Univariate and multivariate analysis].

Ramacciato G, Di Benedetto F, Cautero N, Masetti M, Mercantini P, Corigliano N, Nigri G, Lauro A, Ercolani G, Del Gaudio M, De Ruvo N, Pinna AD.

Chir Ital. 2004 Nov-Dec;56(6):749-59. Italian.

PMID:
15771027
16.

Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes.

Kim JH, Yoon HK, Sung KB, Ko GY, Gwon DI, Shin JH, Song HY.

Cancer. 2008 Oct 1;113(7):1614-22. doi: 10.1002/cncr.23787.

17.

Survival outcomes in resected extrahepatic cholangiocarcinoma: effect of adjuvant radiotherapy in a surveillance, epidemiology, and end results analysis.

Vern-Gross TZ, Shivnani AT, Chen K, Lee CM, Tward JD, MacDonald OK, Crane CH, Talamonti MS, Munoz LL, Small W Jr.

Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):189-98. doi: 10.1016/j.ijrobp.2010.05.001. Epub 2010 Oct 23.

PMID:
20971573
18.

Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus stenting with photodynamic therapy.

Kahaleh M, Mishra R, Shami VM, Northup PG, Berg CL, Bashlor P, Jones P, Ellen K, Weiss GR, Brenin CM, Kurth BE, Rich TA, Adams RB, Yeaton P.

Clin Gastroenterol Hepatol. 2008 Mar;6(3):290-7. doi: 10.1016/j.cgh.2007.12.004. Epub 2008 Feb 6.

PMID:
18255347
19.

A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.

Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T.

Cancer Chemother Pharmacol. 2009 Dec;65(1):113-20. doi: 10.1007/s00280-009-1011-z. Epub 2009 Apr 29.

PMID:
19404641
20.

Evaluation of surgical approach for extrahepatic cholangiocarcinoma.

Shi QF, Liang TB, Qin YS, Wang WL, Shen Y, Zhang M, Zheng SS.

Hepatobiliary Pancreat Dis Int. 2007 Dec;6(6):622-6.

Supplemental Content

Support Center